NCT04045769View on ClinicalTrials.gov

A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 19, 2019

Primary Completion Date

November 27, 2019

Study Completion Date

December 2, 2019

Conditions
Healthy
Interventions
DRUG

Saroglitazar magnesium 4mg

1 tablet of 4 mg Saroglitazar magnesium; 4 tablets of placebo to be administered orally

DRUG

Placebos

5 tablets of placebo to be administered orally

DRUG

Moxifloxacin 400mg

1 tablet of 400 mg Moxifloxacin to be administered orally

DRUG

Saroglitazar magnesium 20 mg

5 tablets of 4 mg Saroglitazar magnesium to be administered orally

Trial Locations (1)

380 054

Cliantha Research Limited, Ahmedabad

All Listed Sponsors
lead

Zydus Therapeutics Inc.

INDUSTRY

NCT04045769 - A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers | Biotech Hunter | Biotech Hunter